Summit Therapeutics Inc. (SMMT): Total Liabilities
$92.32M
As of 2025-12-31
$122.20M
As of 2026-06-30
-44.4%
3-year compound annual growth
+32.0%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $92.32M | +97.2% | 2026-02-23, Balance as of period end |
| 2024-12-31 | $46.81M | -62.6% | 2026-02-23, Balance as of period end |
| 2023-12-31 | $125.26M | -76.7% | 2025-02-24, Balance as of period end |
| 2022-12-31 | $537.51M | n/m | 2024-02-20, Balance as of period end |
| 2021-12-31 | $30.09M | +30.6% | 2023-03-09, Balance as of period end |
| 2020-12-31 | $23.05M | +32.6% | 2022-12-21, Balance as of period end |
| 2019-12-31 | $17.39M | n/a | 2021-03-31, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | 2025-12-31 | $92.32M | +97.2% |
| Aurinia Pharmaceuticals Inc. (AUPH) | 2025-12-31 | $170.26M | -1.7% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $196.03M | +37.9% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $564.23M | +62.8% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $262.35M | -13.0% |
| Vera Therapeutics, Inc. (VERA) | 2025-12-31 | $130.21M | +65.8% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $85.85M | -19.9% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $397.87M | -7.7% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $362.11M | -9.9% |
Compare SMMT, AUPH, KNSA, KURA side by side · Screen every company in Pharmaceutical Preparations ↗